Loading clinical trials...
Loading clinical trials...
Phase 1 Study of Autologous SIRPα-low Macrophages (SIRPant-M) Administered by IT- Injection Alone or in Combination With Focal External-Beam Radiotherapy in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma
Conditions
Interventions
SIRPant-M
External-beam radiotherapy (XRT)
Locations
3
United States
City of Hope
Duarte, California, United States
Hackensack University Medical Center
Hackensack, New Jersey, United States
MD Anderson Cancer Center
Houston, Texas, United States
Start Date
January 17, 2024
Primary Completion Date
June 1, 2025
Completion Date
December 1, 2025
Last Updated
December 20, 2024
NCT06090539
NCT06026319
NCT04851119
NCT06484920
NCT05892718
NCT06550141
Lead Sponsor
SIRPant Immunotherapeutics, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions